Cyclacel pharmaceuticals announces completion of enrollment in the biomarker-enriched patient cohort of its phase 2 study

- patients are preselected for cdkn2a and/or cdkn2b abnormalities - - safety and efficacy data to be reported at an upcoming oncology medical conference - berkeley heights, n.j., sept. 25, 2024 (globe newswire) -- cyclacel pharmaceuticals, inc. (nasdaq: cycc, nasdaq: cyccp; "cyclacel" or the "company"), a biopharmaceutical company developing innovative cancer medicines, today announced that enrollment of 12 patients has been completed as per protocol in cohort 8 of its phase 2 stage, proof of concept 065-101 study of fadraciclib (“fadra”), a cdk2/9 inhibitor, in patients with advanced solid tumors and lymphoma.
CYCC Ratings Summary
CYCC Quant Ranking